Skip to content

Study · Animal study (in vivo) · mouse · 2024

23 results

Abaloparatide is more potent than teriparatide in restoring bone mass and strength in type 1 diabetic male mice.

Marino S, Ozgurel SU, McAndrews K, Cregor M, Villaseñor A, Mamani-Huanca M, Barbas C, Gortazar A, Sato AY, Bellido T

Bone13 Feb 2024Cited by 5 (Europe PMC)

PMID38360197 (opens in a new tab)PMCIDPMC13147481 (opens in a new tab)DOI10.1016/j.bone.2024.117042 (opens in a new tab)PepBankPUB-38360197
Source linkPubMedAsk about this study
Jump to 23 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study23

23 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In control and diabetic mice, abaloparatide increased or restored bone mass more than teriparatide.

    In plain wordsIn mice, abaloparatide increased or restored bone mass more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone mass
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL was superior to PTH in increasing or restoring bone mass in control or T1-MD mice, respectively, which was associated with superior stimulation of trabecular and periosteal bone formation, upregulation of osteoclastic/osteoblastic gene expression, and increased circulating bone remodeling markers.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In control and diabetic mice, teriparatide increased or restored bone mass less than abaloparatide.

    In plain wordsIn mice, teriparatide increased or restored bone mass less than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBone mass
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL was superior to PTH in increasing or restoring bone mass in control or T1-MD mice, respectively, which was associated with superior stimulation of trabecular and periosteal bone formation, upregulation of osteoclastic/osteoblastic gene expression, and increased circulating bone remodeling markers.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In control or diabetic mice, abaloparatide stimulated trabecular bone formation more than teriparatide.

    In plain wordsIn mice, abaloparatide stimulated trabecular bone formation more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrabecular bone formation
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL was superior to PTH in increasing or restoring bone mass in control or T1-MD mice, respectively, which was associated with superior stimulation of trabecular and periosteal bone formation, upregulation of osteoclastic/osteoblastic gene expression, and increased circulating bone remodeling markers.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In control or diabetic mice, teriparatide stimulated trabecular bone formation less than abaloparatide.

    In plain wordsIn mice, teriparatide stimulated trabecular bone formation less than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTrabecular bone formation
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL was superior to PTH in increasing or restoring bone mass in control or T1-MD mice, respectively, which was associated with superior stimulation of trabecular and periosteal bone formation, upregulation of osteoclastic/osteoblastic gene expression, and increased circulating bone remodeling markers.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In control or diabetic mice, abaloparatide stimulated periosteal bone formation more than teriparatide.

    In plain wordsIn mice, abaloparatide stimulated outer bone surface formation more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreasePeriosteal bone formation
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL was superior to PTH in increasing or restoring bone mass in control or T1-MD mice, respectively, which was associated with superior stimulation of trabecular and periosteal bone formation, upregulation of osteoclastic/osteoblastic gene expression, and increased circulating bone remodeling markers.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In control or diabetic mice, teriparatide stimulated periosteal bone formation less than abaloparatide.

    In plain wordsIn mice, teriparatide stimulated outer bone surface formation less than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePeriosteal bone formation
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL was superior to PTH in increasing or restoring bone mass in control or T1-MD mice, respectively, which was associated with superior stimulation of trabecular and periosteal bone formation, upregulation of osteoclastic/osteoblastic gene expression, and increased circulating bone remodeling markers.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In control or diabetic mice, abaloparatide increased osteoclastic/osteoblastic gene expression.

    In plain wordsIn mice, abaloparatide increased bone remodeling gene expression.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOsteoclastic/osteoblastic gene expression
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL was superior to PTH in increasing or restoring bone mass in control or T1-MD mice, respectively, which was associated with superior stimulation of trabecular and periosteal bone formation, upregulation of osteoclastic/osteoblastic gene expression, and increased circulating bone remodeling markers.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In control or diabetic mice, abaloparatide increased circulating bone remodeling markers.

    In plain wordsIn mice, abaloparatide increased blood markers of bone remodeling.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCirculating bone remodeling markers
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL was superior to PTH in increasing or restoring bone mass in control or T1-MD mice, respectively, which was associated with superior stimulation of trabecular and periosteal bone formation, upregulation of osteoclastic/osteoblastic gene expression, and increased circulating bone remodeling markers.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, abaloparatide corrected the diabetes-induced reduction in ultimate load.

    In plain wordsIn mice with diabetes, abaloparatide restored bone load capacity compared with diabetic controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseUltimate load
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Diabetic controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Only ABL corrected the reduction in ultimate load, which is a measure of bone strength, induced by T1-DM, and it also increased energy to ultimate load.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, teriparatide did not correct the diabetes-induced reduction in ultimate load.

    In plain wordsIn mice with diabetes, teriparatide did not restore bone load capacity compared with diabetic controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeUltimate load restoration
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Diabetic controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Only ABL corrected the reduction in ultimate load, which is a measure of bone strength, induced by T1-DM, and it also increased energy to ultimate load.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, abaloparatide increased energy to ultimate load.

    In plain wordsIn mice with diabetes, abaloparatide increased the energy bones absorbed before peak load.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseEnergy to ultimate load
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Only ABL corrected the reduction in ultimate load, which is a measure of bone strength, induced by T1-DM, and it also increased energy to ultimate load.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, abaloparatide increased ultimate stress versus vehicle.

    In plain wordsIn mice with diabetes, abaloparatide increased bone material strength more than vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseUltimate stress
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    In addition, bones from T1-DM mice treated with PTH or ABL exhibited increased ultimate stress, a material index, compared to T1-DM mice administered with vehicle.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, teriparatide increased ultimate stress versus vehicle.

    In plain wordsIn mice with diabetes, teriparatide increased bone material strength more than vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUltimate stress
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    In addition, bones from T1-DM mice treated with PTH or ABL exhibited increased ultimate stress, a material index, compared to T1-DM mice administered with vehicle.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, abaloparatide prevented the diabetes-associated increase in Sost/sclerostin expression.

    In plain wordsIn mice with diabetes, abaloparatide prevented increased sclerostin expression compared with diabetic controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseSost/sclerostin expression
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Diabetic controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    And both PTH and ABL prevented the increased expression of the Wnt antagonist Sost/sclerostin displayed by T1-DM mice.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  15. 15AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, teriparatide prevented the diabetes-associated increase in Sost/sclerostin expression.

    In plain wordsIn mice with diabetes, teriparatide prevented increased sclerostin expression compared with diabetic controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSost/sclerostin expression
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Comparator
    Diabetic controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    And both PTH and ABL prevented the increased expression of the Wnt antagonist Sost/sclerostin displayed by T1-DM mice.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  16. 16AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, abaloparatide increased circulating CTX after 2 weeks, similarly to teriparatide.

    In plain wordsIn mice with diabetes, abaloparatide increased the bone resorption marker CTX similarly to teriparatide after 2 weeks.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCTX at two weeks
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Further, PTH and ABL increased to a similar extent the circulating bone resorption marker CTX and the bone formation marker P1NP in T1-DM after 2 weeks of treatment; however, only ABL sustained these increases after 4 weeks of treatment.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  17. 17AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, teriparatide increased circulating CTX after 2 weeks, similarly to abaloparatide.

    In plain wordsIn mice with diabetes, teriparatide increased the bone resorption marker CTX similarly to abaloparatide after 2 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCTX at two weeks
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Further, PTH and ABL increased to a similar extent the circulating bone resorption marker CTX and the bone formation marker P1NP in T1-DM after 2 weeks of treatment; however, only ABL sustained these increases after 4 weeks of treatment.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  18. 18AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, abaloparatide increased circulating P1NP after 2 weeks, similarly to teriparatide.

    In plain wordsIn mice with diabetes, abaloparatide increased the bone formation marker P1NP similarly to teriparatide after 2 weeks.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseP1NP at two weeks
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Further, PTH and ABL increased to a similar extent the circulating bone resorption marker CTX and the bone formation marker P1NP in T1-DM after 2 weeks of treatment; however, only ABL sustained these increases after 4 weeks of treatment.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  19. 19AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, teriparatide increased circulating P1NP after 2 weeks, similarly to abaloparatide.

    In plain wordsIn mice with diabetes, teriparatide increased the bone formation marker P1NP similarly to abaloparatide after 2 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseP1NP at two weeks
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Further, PTH and ABL increased to a similar extent the circulating bone resorption marker CTX and the bone formation marker P1NP in T1-DM after 2 weeks of treatment; however, only ABL sustained these increases after 4 weeks of treatment.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  20. 20AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, abaloparatide sustained the CTX increase after 4 weeks, unlike teriparatide.

    In plain wordsIn mice with diabetes, abaloparatide sustained increased CTX after 4 weeks, unlike teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSustained CTX increase at four weeks
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Further, PTH and ABL increased to a similar extent the circulating bone resorption marker CTX and the bone formation marker P1NP in T1-DM after 2 weeks of treatment; however, only ABL sustained these increases after 4 weeks of treatment.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  21. 21AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, teriparatide did not sustain the CTX increase after 4 weeks, unlike abaloparatide.

    In plain wordsIn mice with diabetes, teriparatide did not sustain increased CTX after 4 weeks, unlike abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSustained CTX increase at four weeks
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Further, PTH and ABL increased to a similar extent the circulating bone resorption marker CTX and the bone formation marker P1NP in T1-DM after 2 weeks of treatment; however, only ABL sustained these increases after 4 weeks of treatment.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  22. 22AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, abaloparatide sustained the P1NP increase after 4 weeks, unlike teriparatide.

    In plain wordsIn mice with diabetes, abaloparatide sustained increased P1NP after 4 weeks, unlike teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSustained P1NP increase at four weeks
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    47.5 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Further, PTH and ABL increased to a similar extent the circulating bone resorption marker CTX and the bone formation marker P1NP in T1-DM after 2 weeks of treatment; however, only ABL sustained these increases after 4 weeks of treatment.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.
  23. 23AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, teriparatide did not sustain the P1NP increase after 4 weeks, unlike abaloparatide.

    In plain wordsIn mice with diabetes, teriparatide did not sustain increased P1NP after 4 weeks, unlike abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSustained P1NP increase at four weeks
    Study

    mousen: not reported in source

    Male C57Bl/6 J mice with streptozotocin-induced type 1 diabetes or controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 ng/g/day · subcutaneous · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Further, PTH and ABL increased to a similar extent the circulating bone resorption marker CTX and the bone formation marker P1NP in T1-DM after 2 weeks of treatment; however, only ABL sustained these increases after 4 weeks of treatment.
    1 context sentence
    Summary · context
    Intermittent daily subcutaneous injections of equal molar doses (12 pmoles/g/day) of PTH (50 ng/g/day), ABL (47.5 ng/g/day), or vehicle, were administered for 28 days to 5-month-old C57Bl/6 J male mice with established T1-DM or control (C) mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.